Ildong Holdings Co., Ltd stock analysis
Want to see KR:000230 full AI Analyst Report?
Ildong Holdings Co., Ltd (000230) Stock Price & Analysis
000230 Stock Chart & Stats
- Day’s Range
- KRW 5,130.00 - KRW 5,320.00
- 52-Week Range
- KRW 5,130.00 - KRW 17,170.00
- Previous Close
- KRW 5,250.00
- Volume
- N/A
- Average Volume (3M)
- 13.21K
- Market Cap
- KRW 59.28B
- Enterprise Value
- KRW 352.11B
- Total Cash (Recent Filing)
- KRW 80.45B
- Total Debt (Recent Filing)
- KRW 196.55B
- Price to Earnings (P/E)
- 2.2
- Beta
- 0.03
- Next Earnings
- Mar 12, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 30, 2026
- Dividend Yield
- 1.90%
Bulls Say, Bears Say
Bulls Say
Profitability Turnaround
The return to positive operating profit and net income indicates a meaningful recovery from the deep losses of 2021–2023. Healthy gross margin and improved cost control provide a foundation for rebuilding earnings, although continued execution is needed to make the improvement durable.
Positive Cash Generation
Positive operating and free cash flow improve the company’s ability to fund operations, reduce financial pressure, and support investment without relying entirely on external financing. The improvement from 2025 suggests the turnaround is beginning to translate into actual cash generation.
Rebuilt Equity Base
A stronger equity base gives the holding company greater resilience than during its earlier period of financial stress. Improved ROE also indicates that capital is being used more productively, supporting better group-level financial health and capital allocation over the medium term.
Bears Say
Elevated Leverage
Debt remaining above equity limits financial flexibility and can constrain how aggressively the group funds growth or supports subsidiaries. The prior leverage spike also demonstrates that the balance sheet has experienced meaningful stress, making deleveraging important for a more durable recovery.
Volatile Revenue And Earnings Trend
Uneven revenue and margin performance makes it harder to determine whether the recent profitability recovery reflects a durable improvement or an inconsistent rebound. Continued volatility could weaken operating leverage, limit planning visibility, and prevent earnings from compounding steadily.
Weak Cash Conversion
Cash generation has improved, but conversion below net income suggests reported profitability is not yet flowing fully through to cash. Dependence on working-capital timing or limited scaling of operating inflows could reduce the funds available for debt reduction and sustained investment.
000230 FAQ
What was Ildong Holdings Co., Ltd’s price range in the past 12 months?
What is Ildong Holdings Co., Ltd’s market cap?
When is Ildong Holdings Co., Ltd’s upcoming earnings report date?
How were Ildong Holdings Co., Ltd’s earnings last quarter?
Is Ildong Holdings Co., Ltd overvalued?
Does Ildong Holdings Co., Ltd pay dividends?
What is Ildong Holdings Co., Ltd’s EPS estimate?
How many shares outstanding does Ildong Holdings Co., Ltd have?
What happened to Ildong Holdings Co., Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ildong Holdings Co., Ltd?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ildong Holdings Co., Ltd
Ildong Holdings Co., Ltd., established in Seoul, South Korea, in 1941, operates internationally, specializing in the innovation, production, and supply of pharmaceutical goods. The company actively researches and develops novel therapeutics for challenging conditions such as resistant bacteria, various cancers, Alzheimer's disease, obesity, and age-related ailments. Its product portfolio encompasses fundamental ingredients like raw vitamins, probiotics, and antimicrobials, alongside prominent brands such as the lactobacillus product Biovita and the multivitamin Aronamin. Beyond pharmaceuticals, Ildong Holdings is involved in creating and manufacturing health foods and their components. It provides hyaluronic acid for applications in medicine, medical devices, and cosmetics, and offers a range of medical devices designed for aesthetic, plastic surgery, and anti-aging treatments. The company also facilitates online sales of an extensive array of healthcare-related products, including medical equipment, over-the-counter medicines, dietary supplements, food, beverages, cosmetics, and sanitary items. Furthermore, Ildong Holdings delivers beauty and cosmetic surgery services, along with pharmaceutical system integration (SI) consulting, system design and implementation, RFID and barcode solutions, and other specialized services, in addition to an advertising division. The entity adopted its current name, Ildong Holdings Co., Ltd., in August 2016, having previously operated as Ildong Pharmaceutical Co., Ltd.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Woongseop Yoon
- Employees
- 80
- Website
- www.ildongholdings.co.kr
- Address
- 2, Baumoe-ro 27-gil, Seoul, SL, 06752, KR
Ildong Holdings Co., Ltd (000230) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |

